{"result": "(\"entity\"<|>LIRAGLUTIDA<|>ORGANIZATION<|>Liraglutida is a medication used for weight loss and diabetes management, specifically in the form of Saxenda® and is involved in various clinical studies for its effectiveness.)\n##\n(\"entity\"<|>SCALE DIABETES<|>EVENT<|>The SCALE Diabetes study is a clinical trial that involved 846 patients with type 2 diabetes to evaluate the effectiveness of liraglutida 3 mg.)\n##\n(\"entity\"<|>SCALE PREDIABETES<|>EVENT<|>The SCALE Prediabetes study is a clinical trial aimed at assessing the effects of liraglutida on patients with prediabetes.)\n##\n(\"entity\"<|>SCALE MANTENIMIENTO<|>EVENT<|>The SCALE Mantenimiento study is a clinical trial that confirms the effectiveness of liraglutida 3 mg in maintaining weight loss.)\n##\n(\"entity\"<|>SCALE SAHS<|>EVENT<|>The SCALE SAHS study focuses on the effects of liraglutida in patients with sleep apnea-hypopnea syndrome.)\n##\n(\"entity\"<|>OBESIDAD<|>EVENT<|>Obesidad refers to the condition of being overweight, which is a focus of the clinical studies involving liraglutida.)\n##\n(\"relationship\"<|>LIRAGLUTIDA<|>SCALE DIABETES<|>Liraglutida was the medication tested in the SCALE Diabetes study to evaluate its effectiveness in managing type 2 diabetes<|>8)\n##\n(\"relationship\"<|>LIRAGLUTIDA<|>SCALE PREDIABETES<|>Liraglutida was the medication tested in the SCALE Prediabetes study to assess its effects on patients with prediabetes<|>8)\n##\n(\"relationship\"<|>LIRAGLUTIDA<|>SCALE MANTENIMIENTO<|>Liraglutida was the medication evaluated in the SCALE Mantenimiento study for its role in maintaining weight loss<|>8)\n##\n(\"relationship\"<|>LIRAGLUTIDA<|>SCALE SAHS<|>Liraglutida was tested in the SCALE SAHS study to determine its effects on patients with sleep apnea-hypopnea syndrome<|>8)\n##\n(\"relationship\"<|>SCALE DIABETES<|>OBESIDAD<|>The SCALE Diabetes study involved patients with obesity to evaluate the effectiveness of liraglutida<|>6)\n##\n(\"relationship\"<|>SCALE PREDIABETES<|>OBESIDAD<|>The SCALE Prediabetes study included patients with obesity to assess the effects of liraglutida<|>6)\n##\n(\"relationship\"<|>SCALE MANTENIMIENTO<|>OBESIDAD<|>The SCALE Mantenimiento study focused on maintaining weight loss in patients with obesity<|>6)\n##\n(\"relationship\"<|>SCALE SAHS<|>OBESIDAD<|>The SCALE SAHS study examined the effects of liraglutida on weight loss in patients with obesity and sleep apnea<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: -3 kg de promedio en las personas con                             jetivó que la pérdida de peso de ambos grupos al cabo\n   diabetes que son tratadas con liraglutida a las dosis\n   mencionadas24. Pero precisamente fue este efecto inhi-                        de 56 semanas fue del 8% (2,6% con placebo). Ade-\n                                                                                 más, liraglutida 3 mg redujo en 8 veces la posibilidad\n   bidor del apetito lo que favoreció el desarrollo de lira-                     de que el paciente con prediabetes evolucionara a dia-\n   glutida     3  mg     (Saxenda®).      El  desarrollo     clínico   de        betes (OR 8,1; IC 95%: 2,6 a 25,3)26.\n   liraglutida 3 mg hasta su comercialización consta de                             En el estudio SCALE diabetes participaron 846 pa-\n   un estudio en fase II y cuatro estudios en fase III.                          cientes con diabetes tipo 2, con el mismo esquema de\n      El estudio de fase II tenía por finalidad conocer cuál                     tratamiento de liraglutida 3 mg frente a placebo, pero\n   era la dosis más efectiva para perder peso. Se incluye-                       incluyendo también la dosis habitual empleada para el\n   ron 564 pacientes con obesidad y sin diabetes que fue-                        control de la diabetes (1,8 mg/día). Tras un año de tra-\n   ron asignados a diferentes dosis de liraglutida (1,2-                         tamiento, se constató que el control glucémico es simi-\n\n\n\n                   Obesidad (fase II)         SCALE Prediabetes          SCALE Diabetes        SCALE Mantenimiento             SCALE SAHS\n              0                                                                                       –0,2\n             –1\n             –2                                                              –2                                                 –1,6\n             –3                                   –2,6\n                        –3,1\n             –4\n             –5\n             –6                                                                     –6                                                 –5,7\n                                                                                                             –6,2\n             –7\n             –8                                            –8\n             –9\n                                –9,2                                                                           Placebo         Liraglutida 3.0\n           –10\n\n\n\n                       27,6      75,0              27,1     63,2              13,8     49,9            21,5     50,5            18,5      46,3\n\n\n\n            Sujetos que pierden > 5% peso            Placebo         Lira 3\n\n\n\n   Figura 1.     Resultados de los estudios SCALE (Satiety and Clinical Adiposity - Liraglutide Evidence).\n---\n 138      BLOQUE: ALTERACIONES DE LA ENERGÍA\n\n\n\nlar para ambas dosis de liragutida, pero la pérdida de                    Contraindicaciones y precauciones:            Liraglutida 3 mg\npeso es mayor, alrededor del 6%, en el grupo de lira-                  está contraindicada en pacientes con neoplasia endocri-\nglutida 3 mg frente al 2% de placebo27.                                na múltiple (MEN-2), antecedentes de carcinoma medu-\n   Los otros dos estudios SCALE se realizaron para ob-                 lar de tiroides, en enfermedad renal o hepática avanza-\nservar las acciones del fármaco en otras situaciones.                  da, en embarazadas y lactantes, presencia de pancreatitis\nAsí, en el estudio SCALE-mantenimiento28, se confirma                  o colecistitis. Tampoco hay experiencia en adolescentes\nque liraglutida 3 mg contribuye a que los pacientes                    (< 18 años) o mayores de 75 años. Se debe emplear con\nque habían perdido un promedio de un 6% de peso                        precaución en casos con antecedentes de colelitiasis,\ncorporal con dieta, conseguían añadir otro 6% de pér-                  pancreatitis, gastroparesia o ideación suicida.\ndida de peso adicional al ser tratados con el agonista                    De manera conjunta y atendiendo a los resultados\nde GLP1. El último estudio a 32 semanas con liragluti-                 principales de los ensayos clínicos de cada fármaco de\nda 3 mg se realizó en un grupo de pacientes con sín-                   los aquí comentados, podemos advertir que la asocia-\ndrome de apneas-hiponeas del sueño (SAHS) que no                       ción de FEN/TPM es la combinación más eficaz para\npodían o no querían utilizar el CPAP (SCALE-apneas del\nsueño)29. En este grupo, la pérdida de peso, similar a                 perder peso, siendo orlistat el que menos efecto tiene\n                                                                       sobre el peso corporal (figura 2).\nlos estudios anteriores, supuso además una disminu-\nción paralela del número de apneas de estos sujetos29.                 4.   Futuro de los tratamientos para\n   En conjunto, liraglutida presenta una OR de 5,54 (IC                     la obesidad\n95%, 4,16-7\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}